Product name

Therapeutic Candidate and Target for Treating AMD

Summary

Identification of a new target (CD36) and several families of LEAD compounds (small molecules) for the treatment of Age-related Macular Degeneration (AMD), including the wet AND dry forms.

Organization name

UnivalorMontréal, Quebec, Canada

Profile

New Approach for Age-Related Macular Degeneration

Origin: Drs Huy Ong, William Lubell, Sylvain Chemtob, et al. from the Université de Montréal.

Indication: AMD

Field: Opthalmology

Molecule type: NCE - New Chemical Entity

Molecule 1: A family of unnatural azapeptide

MoA: Selective modulation of the CD36 receptor, preventing lipid accumulation

Highlights:

• Proof of principle completed - Binding studies demonstrating specificity towards CD36
• Proof of concept ex vivo: inhibition of angiogenesis in rat aortic ring model
• Proof of concept in vivo - Inhibition of choroidal neovascularisation using laser injury murine model
• The compounds are anti-angiogenic and they inhibit the development of choroidal neovascularisation in vivo in a CD36 dependent manner.
• The compounds selectively bind to CD36.
• The compounds inhibit in vitro vascular sprouting of aortic endothelium.
• The compounds inhibit choroidal neovascularisation in vivo as assessed using the model of laser injury induced neovascularisation. 
• The compounds can be used to treat choroidal neovascularisation in age- related macular degeneration.

IP STATUS:   

PCT, filed 2008/06; A novel class of azapeptide compounds.

Also, US provisional filed in 2008/02 (target for dry AMD).

Contact:

Louis Provencher
Manager Business Development, Life Sciences
louis.provencher(at)univalor.ca

About Univalor

Gestion Univalor, Limited partnership ("Univalor") is a limited partnership whose mission is to commercialize discoveries made by researchers at the Université de Montréal, the École Polytechnique de Montréal, the CHU Sainte-Justine, Mother and Child University Hospital Center, the HEC Montréal, the Hôpital Maisonneuve-Rosemont, the Hôpital du Sacré-Coeur de Montréal, the Institut de recherches cliniques de Montréal and the Institut universitaire de gériatrie de Montréal.

Univalor also provides commercialization services to the limited partnerships of the following hospital centres affiliated with the Université de Montréal, the Centre hospitalier universitaire de Montréal (CHUM) and the Montréal Heart Institute.

Description File

 en_val566.doc

URL

http://www.univalor.ca

Your feedback

back

Search

Sector

--- select from list ---AgroBiotechnologyBiomedicine, DiagnosticsCosmeticsEnabling Technology, Platform TechnologyEnvironmentalFine ChemicalsFoodMedical DeviceProduction, Development ServicesVeterinary

Technology

--- select from list ---AnalyticalAnimal ModelAntibody BasedAntisense, NucleotideBioinformaticBiologicalBlood Products, SubstitutesBreeding, CultivationChemistryClinical Research ServicesCompound LibrariesDiagnostic Assay, KitDrug DeliveryDrug DiscoveryDrugs, Small MoleculeEngineeringEnzymesGene Therapy, VectorsGenomicsHigh Throughput ScreeningImagingImplantIndustrial Waste Treatment, RemediationNanotechnologyNatural ProductsPeptides, ProteinsPharmacogenomicsPreclinical Research ServiceProteomicsReagents, Media RegenerationRenewable resourcesSurgical InstrumentationTissue Engineering, BiomaterialTransgenic OrganismTransplantVaccines

Development Stage

--- select from list ---Clinical Phase IClinical Phase IIClinical Phase IIIClinical Phase IV/MarketedIdea, Conceptin-vitro TestingLead Compound/SeriesPreclinicalProof-of-principlePrototypeRepurposingTarget Identification, Validation, Drug Discovery

Disease Category

--- select from list ---(Auto) ImmuneCancerous, neoplasmaticInfectious, ParasiticInflammatoryInherited, NeonatalMetabolic, EndocrineOther, organ-specific diseases

Organ

--- select from list ---BloodBoneBrainBreastCardiovascularCartilageCNS, Nerves, SpineEarEsophagusEyeGynecologyHeartImmune SystemIntestineLiverMusclePancreasPNSProstate and male sexual healthPsychiatry, psychologyRespiratorySkinTeethUrology, kidney